Caliway Biopharmaceuticals Co., Ltd.
Research Caliway Biopharmaceuticals Co., Ltd. (6919.TW) on Bullrun: market cap TWD 119.69B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6919.TW
- ExchangeTW
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyTWD
- Market capTWD 119.69B
- Financial periodQ2 2026
- RevenueTWD 3.57M
- Net income-TWD 222.52M
- Free cash flow-TWD 134.54M
- Gross margin65.3%
Valuation Snapshot
latest market cap is TWD 119.69B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 119.69B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 TWD.
About Caliway Biopharmaceuticals Co., Ltd.
Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum's disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements.
ETFs that hold Caliway Biopharmaceuticals Co., Ltd.
US-listed ETFs
Caliway Biopharmaceuticals Co., Ltd. is held by 38 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| iShares MSCI Emerging Markets ETF (EEM) | 0.03% | 0.72% |
| iShares Core MSCI Emerging Markets ETF (IEMG) | 0.02% | 0.09% |
| iShares MSCI Taiwan ETF (EWT) | 0.26% | 0.59% |
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | 0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | 0.03% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| iShares MSCI ACWI ETF (ACWI) | <0.01% | 0.32% |
| iShares MSCI ACWI ex U.S. ETF (ACWX) | 0.01% | 0.32% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Caliway Biopharmaceuticals Co., Ltd.'s market cap?
Caliway Biopharmaceuticals Co., Ltd.'s market capitalization is TWD 119.69B.
What does Caliway Biopharmaceuticals Co., Ltd. do?
Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum's disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements. The company was incorporated in 2012 and is based in New Taipei City, Taiwan.